MaxCyte, Inc. HC Wainright & Co Virtual Conference Presentation
10 September 2020 - 4:00PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
10 September 2020
MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co
22nd Annual Global Investment Virtual Conference
GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT,
MXCL), a global cell-based therapies and life sciences company,
today announced that CEO Doug Doerfler plans to present an overview
of the company at the upcoming H.C. Wainright & Co 22nd Annual
Global Investment Virtual Conference taking place September 14-16,
2020. Details are as follows:
Presentation Date/Time: Monday, September 14, at 4:00 p.m.
EDT
Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is
headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
Ashley Tapp
--------------------------------------------------------------
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAKKCBNOBKDBCK
(END) Dow Jones Newswires
September 10, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024